 |
 |
|
|
|
Milton H. Ellis President Milton H. Ellis has had thirty years of international and domestic pharmaceutical experience. He was instrumental in developing Bristol Myers Squibb's anti-cancer business on a global basis and was General Manager of their pharmaceutical business in Australia. He co-founded Orphan Pharmaceuticals USA, Inc., in 1991 and has been President since that time. He brings with him extensive international experience in pharmaceutical marketing, licensing and manufacturing. In 2000, Mr. Ellis received the prestigious National Organization of Rare Disorders Corporate Award for work in developing a treatment for Hereditary Tyrosinemia Type 1. |
 |
Kathy Hare Project Manager Kathy Hare works in the important role as the Project Manager. She has a broad medical background in nursing and medical technology, specializing in Hematology, Oncology, Flow Cytometry and Cytogenetics. She received her B.S. in Medical Technology and Master's in Organizational Management from Trevecca University. Her current focus is on logistical support for our ongoing clinical trials as well as researching and assessing orphan market dynamics, as well as evaluation of new product potential and planning. |
|
 |
W. Darrell Moseley Director W. Darrell Moseley holds a B. A. Degree from the University of Georgia and a second degree from the American Graduate School of International Management in Phoenix, Arizona. Mr. Moseley has over forty five years of experience in international and domestic health care markets. After initiating his career with Mead Johnson International, Mr. Moseley served in various positions in sales and marketing with Wyeth laboratories. Notably, he was an international Area Vice President with Abbott Laboratories for nine years managing the company's business in sixty-seven countries. In 1976, Mr. Moseley founded Basic Services international, a health care consulting firm which he continues to serve as president. Additionally, Moseley has held several interim assignments in marketing and professional relations at Biotherapeutics, Inc. and Therapeutic Antibodies, Inc. |
